Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence-Reference-Cited by-同舟云学术

Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence

Published:2023-01-24 Issue:3 Volume:18 Page:231-245
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Convertino Irma¹^ORCID,Ferraro Sara¹^ORCID,Cappello Emiliano¹^ORCID,Valdiserra Giulia¹^ORCID,Bonaso Marco¹^ORCID,Tuccori Marco¹²^ORCID

Affiliation:

1. Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

2. Unit of Adverse Drug Reactions Monitoring, Pisa University Hospital, Pisa, Italy

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2023.2170348

Reference63 articles.

1. Cromer Berman S Emergency Use Authorization (EUA) for EVUSHELD (Tixagevimab 150 mg and Ci lgavimab 150 mg injection co-packaged for intramuscular use) center for drug evaluation and research (CDER) review identifying information application type (EUA or Pre-EUA) EUA If E. FDA website. https://www.fda.gov/media/155107/download. Published 2021. Accessed 2021. Accessed Jun 27, 2022 Jun 27.

2. Evusheld | European medicines agency. https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld. Published 2022. Accessed 2022. Accessed Oct 10, 2022 Oct 10.

3. Agenzia Italiana del Farmaco (AIFA). AIFA autorizza l’utilizzo terapeutico del monoclonale Evusheld per il trattamento precoce del COVID-19 in soggetti a rischio di progressione. AIFA official website. https://www.aifa.gov.it/-/aifa-autorizza-l-utilizzo-terapeutico-del-monoclonale-evusheld-per-il-trattamento-precoce-del-covid-19-in-soggetti-a-rischio-di-progressione. Accessed 2022 Oct 10.

4. EMA Committee for Medicinal Products for Human Use (CHMP). Committee for medicinal products for human use (CHMP) assessment report. EMA website. www.ema.europa.eu/contact. Published 2021. Accessed June 27, 2022.

5. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups;Immunity, Inflammation and Disease;2024-06

2. Assessing the post hoc effectiveness of tixagevimab−cilgavimab for prevention of SARS‐CoV‐2 infections in solid organ transplant recipients;Transplant Infectious Disease;2023-10-27

3. Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option;Expert Opinion on Drug Discovery;2023-10-13

4. Current options of covid-19 management in 2023;Medicína pro praxi;2023-09-26

5. SARS-CoV-2 spike S2-specific neutralizing antibodies;Emerging Microbes & Infections;2023-06-15